U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
Commission File Number 0-23031
NOTIFICATION OF LATE FILING
(Check One): [ ] Form 10-K and 10-KSB [ ] Form 11-K [ ] Form 20-F
[X] Form 10-Q and 10-QSB [ ] Form N-SAR
For the Period Ended: June 30, 2000
-------------
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: ________________
Read attached instruction sheet before preparing form. Please print or
type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates:
PART I
REGISTRANT INFORMATION
Dynamic Health Products, Inc.
---------------------------------------
Full Name of Registrant
---------------------------------
Former Name if Applicable
6950 Bryan Dairy Road
---------------------------------
Address of Principal Executive Office (Street and Number)
Largo, Florida 33777
-----------------------------
City, State and Zip Code
<PAGE>
PART II
RULE 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate.)
[X] | (a) The reasons described in reasonable detail in Part III of this
| form could not be eliminated without unreasonable effort or
| expense;
|
[ ] | (b) The subject annual report, semi-annual report, transition report
| on Form 10-K, Form 20-F, Form 11-K or Form N-SAR, or portion
| thereof will be filed on or before the 15th calendar day
| following the prescribed due date; or the subject quarterly
| report or transition report on Form 10-Q, or portion thereof will
| be filed on or before the fifth calendar day following the
| prescribed due date; and
|
[ ] | (c) The accountant's statement or other exhibit required by Rule
| 12b-25(c) has been attached if applicable.
PART III
NARRATIVE
State below in reasonable detail why the Form 10-K, 11-K, 20-F 10-Q, N-SAR
or the transition report portion thereof could not be filed within the
prescribed time period. (Attach extra sheets if needed.)
Dynamic Health Products, Inc. (the "Company") could not file its Form
10-QSB for the three months ended June 30, 2000 within the prescribed time
period because of a delay in receipt of information requested from a third
party, thus causing a delay in the accurate completion of the Company's
consolidated financial statements for the period.
The Company is diligently working to complete the Form 10-QSB and expects
to file it in its entirety on or before the fifth calendar day following the
prescribed due date.
<PAGE>
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Carol Dore-Falcone 727 544-8866
---------------------------------------------------------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is
no, identify report(s).
[X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof?
[X] Yes [ ] No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
See Attachment A.
Dynamic Health Products, Inc.
----------------------------------------------------------------
(Name of Registrant as Specified in Charter)
Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: August 14, 2000 By: /s/ Carol Dore-Falcone
------------------------------- --------------------------------
Name: Carol Dore-Falcone
--------------------------------
Title: Chief Financial Officer
-------------------------------
INSTRUCTION: The form may be signed by an executive officer of the
registrant or by any other duly authorized representative. The name and
title of the person signing the form shall be typed or printed beneath the
signature. If the statement is signed on behalf of the registrant by an
authorized representative (other than an executive officer), evidence of
the representative's authority to sign on behalf of the registrant shall be
filed with the form.
<PAGE>
ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (see 18 U.S.C. 1001).
GENERAL INSTRUCTIONS
1. This form is required by Rule 12b-25 of the General Rules and
Regulations under the Securities Exchange Act of 1934.
2. One signed original and four conformed copies of this form and
amendments thereto must be completed and filed with the Securities and Exchange
Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General
Rules and Regulations under the Act. The information contained in or filed with
the form will be made a matter of public record in the Commission files.
3. A manually signed copy of the form and amendments thereto shall be filed
with each national securities exchange on which any class of securities of the
registrant is registered.
4. Amendments to the notifications must also be filed on Form 12b-25 but
need not restate information that has been correctly furnished. The form shall
be clearly identified as an amended notification.
5. ELECTRONIC FILERS. This form shall not be used by electronic filers
unable to timely file a report solely due to electronic difficulties. Filers
unable to submit a report within the time period prescribed due to difficulties
in electronic filing should comply with either Rule 201 or Rule 202 of
Regulation S-T or apply for an adjustment in filing date pursuant to Rule 13(b)
of Regulation S-T.
(Form 12b-25-07/98)
<PAGE>
ATTACHMENT A
The Company expects that results of operations for the three months
ended June 30, 2000 will not be comparable to the three months ended June 30,
1999 primarily due to two facts.
First, for the three months ended June 30, 1999, the Company had
distribution revenues of approximately $12.2 million and net income of
approximately $41,000 from its subsidiary, Becan Distributors, Inc. and its
subsidiary Discount Rx, Inc. (collectively "Becan"), which was subsequently sold
by the Company on November 26, 1999.
Second, for the three months ended June 30, 2000, the Company had
distribution revenues of approximately $1.9 million and net income of
approximately $251,000 from its subsidiary, Dynamic Life Korea LTD, which
commenced operations in April 2000.
